Search

Yoshinori T Kohwi

from El Cerrito, CA
Age ~75
Get Report
Also known as:
Yoshinori T Kowh, Yoshinon Kohwi, Yoshinor Kohwi, Yoshinori Koi, Kohwi Yoshinori, Yoshinori I, Kathleen Trotta
Phone and address:
2620 Arlington Blvd, Richmond, CA 94530
(510) 233-1326
Related to:
Staci J TrottoShigematsu T KohwiAndrew Trotto, 51Terumi K Kohwi, 75Minoree Kohwi, 46Frank Vincent TrottaKathleen A Trotta, 74
Connected to:
Levi D Koi, 41Thomas J Koickal, 60Dorcas Koida, 92Masanori Koide, 104Tetsuya Koide, 56Hiroko Koike, 77Janis I Koike, 81Kazuo Koike, 86Linda M Koike, 79Madoka Koike, 46

Yoshinori Kohwi Phones & Addresses

  • 2620 Arlington Blvd, El Cerrito, CA 94530 (510) 233-1326
  • Richmond, CA
  • 2991 Shasta Rd, Berkeley, CA 94708
  • Del Mar, CA
  • San Diego, CA
  • Alameda, CA

Publications

Us Patents

Satb1: A Determinant Of Morphogenesis And Tumor Metastasis

View page
US Patent:
20080280298, Nov 13, 2008
Filed:
Mar 28, 2008
Appl. No.:
12/058574
Inventors:
Hye-Jung Han - Albany CA, US
Yoshinori Kohwi - El Cerrito CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68
G01N 33/574
C12N 5/02
C07H 21/04
US Classification:
435 6, 435 723, 435375, 536 245
Abstract:
It is proposed that cancer cells express SATB1, and that SATB1 acts as a determinant for the acquisition of metastatic activity by controlling expression of a specific set of genes that promote metastatic activity. In order for cancer cells to gain the ability to metastasize, SATB1 re-organizes or re-packages genomic sequences in a specific manner to allow a switch in the pattern of gene expression. SATB1 expression was found restricted mainly to aggressive cancer cells where it may regulate the genetic and epigenetic changes that program the steps involved in the metastatic process. The present invention describes reagents and tools to detect the SATB1 protein for use in diagnosis and prognosis of aggressive cancers and therapeutics to inhibit SATB1 protein to deplete its expression in metastatic and aggressive cancers.

Potential Prognostic Markers And Therapeutic Targets For Neurological Disorders

View page
US Patent:
20110230547, Sep 22, 2011
Filed:
Dec 16, 2010
Appl. No.:
12/970878
Inventors:
Yoshinori Kohwi - El Cerrito CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/7088
C07H 21/04
A61P 25/00
A01K 67/00
C40B 40/06
C12Q 1/68
US Classification:
514 44 R, 536 231, 800 13, 800 18, 800 9, 506 16, 435 611
Abstract:
We recently found that Satb1 is expressed highly by mature neurons in specific regions of the postnatal brain. Satb2, a homolog of Satb1, is expressed at low levels in the postnatal brain. Neurons respond to external stimuli and rapidly and dynamically change their expression. Satb1 has been found to directly regulate a set of genes in the postnatal brain, presumably playing a crucial role as a ‘genome organizer’ for brain function and behaviors. Satb2 may also have a similar function, even though it is expressed at low levels in the postnatal brain. The present invention describes compositions, reagents and tools using wild type and variant SATB1 and SATB2 genes and proteins for use in diagnosis, prognosis and therapeutics in neurological dysfunction and psychiatric disorders.

Cancer-Associated Mar Binding Protein

View page
US Patent:
56247990, Apr 29, 1997
Filed:
Feb 13, 1995
Appl. No.:
8/388023
Inventors:
Yoshinori Kohwi - San Diego CA
Assignee:
The Burnham Institute - La Jolla CA
International Classification:
C12Q 168
G01N 33574
G01N 33566
G01N 3348
US Classification:
435 6
Abstract:
The present invention provides a substantially purified protein, p114-MBP, which has an apparent molecular mass of about 114 kDa and specifically associates with a matrix attachment region DNA sequence context (MAR). p114-MBP is characterized, in part, by having substantial MAR binding activity in malignant tumor tissue but not in a corresponding non-cancerous tissue. The invention also provides a method of detecting the presence of malignant tumor tissue in a cell sample suspected of containing malignant tumor tissue by contacting the sample with a MAR, under conditions that allow the specific association of the MAR with p114-MBP, and detecting such specific association, which indicates the presence of malignant tumor tissue in the cell sample. The present invention further provides a method of diagnosing cancer in a subject suspected of having cancer by contacting a cell sample obtained from a subject with a MAR under conditions that allow the specific association of the MAR with p114-MBP and detecting such specific association, which indicates that malignant tumor tissue was present in the sample and, therefore, is diagnostic of cancer in the subject. The invention also provides a method of determining the prognosis of a cancer patient.

Matrix-Associating Dna-Binding Protein, Nucleic Acids Encoding The Same And Methods For Detecting The Nucleic Acids

View page
US Patent:
56523408, Jul 29, 1997
Filed:
Jun 6, 1995
Appl. No.:
8/473122
Inventors:
Yoshinori Kohwi - San Diego CA
Liliane A. Dickinson - San Diego CA
Assignee:
La Jolla Cancer Research Foundation - La Jolla CA
International Classification:
A61K 3817
US Classification:
530358
Abstract:
The present invention provides a novel human protein, SATB1, that binds matrix/scaffold-associating DNA regions (MARs). The novel human protein, predominantly expressed in the thymus, has an approximate molecular weight of about 85. 9 kD. The SATB1 cDNA encodes a 763 amino acid sequence protein that is capable of binding to special AT rich sequences (ATC sequences). The invention further provides antibodies specifically reactive with such protein. Isolated nucleic acids encoding the novel MAR-binding protein are also provided, as well as vectors containing the nucleic acids and recombinant host cells transformed with such vectors. The invention further provides methods of detecting such nucleic acids by contacting a sample with a nucleic acid probe having a nucleotide sequence capable of hybridizing with the isolated nucleic acids of the present invention. Such probes can correspond to the ATC sequences.

Matrix-Associating Dna-Binding Protein, Nucleic Acids Encoding The Same And Methods For Detecting The Nucleic Acids

View page
US Patent:
63334070, Dec 25, 2001
Filed:
Jun 7, 1995
Appl. No.:
8/481659
Inventors:
Yoshinori Kohwi - San Diego CA
Liliane A. Dickinson - San Diego CA
Assignee:
La Jolla Cancer Research Foundation - La Jolla CA
International Classification:
C12N 1509
C12N 1512
US Classification:
536 241
Abstract:
Isolated nucleic acids encoding a novel MAR-binding protein are also provided, as well as vectors containing the nucleic acids and recombinant host cells transformed with such vectors. The invention further provides methods of detecting such nucleic acids by contacting a sample with a nucleic acid probe having a nucleotide sequence capable of hybridizing with the isolated nucleic acids of the present invention. Such probes can correspond to the ATC sequences.

Antibodies Having Specific Reactivity For A Matrix-Associating Dna-Binding Protein

View page
US Patent:
58696210, Feb 9, 1999
Filed:
Jun 7, 1995
Appl. No.:
8/472478
Inventors:
Yoshinori Kohwi - San Diego CA
Liliane A. Dickinson - San Diego CA
Assignee:
La Jolla Cancer Research Foundation - La Jolla CA
International Classification:
C07K 1618
C07K 1644
US Classification:
5303879
Abstract:
The present invention provides a novel human protein, SATB1, that binds matrix/scaffold-associating DNA regions (MARs). The novel human protein, predominantly expressed in the thymus, has an approximate molecular weight of about 85. 9 kD. The SATB1 cDNA encodes a 763 amino acid sequence protein that is capable of binding to special AT rich sequences (ATC sequences). The invention further provides antibodies specifically reactive with such protein. Isolated nucleic acids encoding the novel MAR-binding protein are also provided, as well as vectors containing the nucleic acids and recombinant host cells transformed with such vectors. The invention further provides methods of detecting such nucleic acids by contacting a sample with a nucleic acid probe having a nucleotide sequence capable of hybridizing with the isolated nucleic acids of the present invention. Such probes can correspond to the ATC sequences.

Long Non-Coding Rna Expressed In Aggressive Cancer

View page
US Patent:
20170067125, Mar 9, 2017
Filed:
Nov 16, 2016
Appl. No.:
15/353710
Inventors:
- Oakland CA, US
Yoshinori Kohwi - El Cerrito CA, US
Ellen C. Ordinario - Oakland CA, US
Michael A. Balamotis - Oakland CA, US
Hye-Jung Han - Lafayette CA, US
International Classification:
C12Q 1/68
Abstract:
The invention described in the application relates to a long non-coding RNA expressed in cancer. The invention thus provides methods and compositions for evaluating levels of the long non-coding RNA to assess the aggressiveness of a cancer and for modulating levels of the long non-coding RNA.

Satb1: A Determinant Of Morphogenesis And Tumor Metastatis

View page
US Patent:
20150323536, Nov 12, 2015
Filed:
Nov 13, 2014
Appl. No.:
14/540991
Inventors:
- Oakland CA, US
Hye-Jung Han - Albany CA, US
Yoshinori Kohwi - El Cerrito CA, US
International Classification:
G01N 33/574
C12N 15/113
A61K 31/7105
C07K 16/18
C12N 15/115
C12Q 1/68
A61K 31/713
Abstract:
It is proposed that cancer cells express SATB1, and that SATB1 acts as a determinant for the acquisition of metastatic activity by controlling expression of a specific set of genes that promote metastatic activity. In order for cancer cells to gain the ability to metastasize, SATB1 re-organizes or re-packages genomic sequences in a specific manner to allow a switch in the pattern of gene expression. SATB1 expression was found restricted mainly to aggressive cancer cells where it may regulate the genetic and epigenetic changes that program the steps involved in the metastatic process. The present invention describes reagents and tools to detect the SATB1 protein for use in diagnosis and prognosis of aggressive cancers and therapeutics to inhibit SATB1 protein to deplete its expression in metastatic and aggressive cancers.
Control profile
Yoshinori T Kohwi from El Cerrito, CA, age ~75 Get Report